Anthrax vaccine showdown as PharmAthene’s SparVax Phase II gets FDA go ahead

PharmAthene have announced that the FDA has lifted the clinical hold previously placed on the Phase II study of it's next generation anthrax vaccine, SparVax. The FDA had originally placed a hold on the trial back in August 2012, requesting that PharmaAthene "provide additional stability data for both its engineering and GMP lots of U.S. manufactured Final Drug Product, as …

Is it ethical to test the anthrax vaccine in children?

A US presidential commission has given a tentative thumbs-up to the testing of the anthrax vaccine in children. The report released by the Presidential Commission for the Study of Bioethical Issues described the necessity of testing the vaccine on children, but also detailed strict guidelines for testing to keep children at minimal risk. “The safety of our children is paramount, …

Development of a recombinant protective antigen (rPA) based anthrax vaccine

Thomas Fuerst, Executive Vice President, Chief Scientific Officer from PharmAthene joined us at the World Vaccine Congress 2012 in Lyon to give details about the development of a recombinant protective antigen (rPA) based anthrax vaccine. His presentation focused on the following points: Use of modern vaccine production technologies for the manufacture of SparVaxâ„¢ Well characterized recombinant Protective Antigen (rPA) anthrax …

Presentation download: Development of a recombinant protective antigen (rPA) based anthrax vaccine

Thomas Fuerst, Executive Vice President, Chief Scientific Officer from PharmAthene joined us at the World Vaccine Congress 2012 in Washington to give details about the development of a recombinant protective antigen (rPA) based anthrax vaccine. In his presentation he detailed: · Background Information – Next Generation Vaccine · Development of a Robust Manufacturing Platform · Analytical Methods for Purity and …